Adhesion and immunomodulatory effects of *Bifidobacterium lactis* HN019 on intestinal epithelial cells INT-407

Chang Liu, Zhuo-Yang Zhang, Ke Dong, Xiao-Kui Guo

AIM: To elucidate the adherence and immunomodulatory properties of a probiotic strain *Bifidobacterium lactis* (B. lactis) HN019.

METHODS: Adhesion assays of *B. lactis* HN019 and *Salmonella typhimurium* (*S. typhimurium*) ATCC 14028 to INT-407 cells were carried out by detecting copies of species-specific genes with real-time polymerase chain reaction. Morphological study was further conducted by transmission electron microscopy. *Interleukin-1β (IL-1β)*, *interleukin-8*, and *tumor necrosis factor-α (TNF-α)* gene expression were assessed while enzyme linked immunosorbent assay was used to detect IL-8 protein secretion.

RESULTS: The attachment of *S. typhimurium* ATCC 14028 to INT-407 intestinal epithelial cells was inhibited significantly by *B. lactis* HN019. *B. lactis* HN019 could be internalized into the INT-407 cells and attenuated IL-8 mRNA level at both baseline and *S. typhimurium*-induced pro-inflammatory responses. IL-8 secretion was reduced while IL-1β and TNF-α mRNA expression level remained unchanged at baseline after treated with *B. lactis* HN019.

CONCLUSION: *B. lactis* HN019 does not up-regulate the intestinal epithelium expressed pro-inflammatory cytokine, it showed the potential to protect enterocytes from an acute inflammatory response induced by enteropathogen.

© 2010 Baishideng. All rights reserved.

Key words: Probiotics; Intestinal epithelium; Enteropathogen; Immunomodulation; Adhesion

INTRODUCTION

The intestinal tract acts as a reservoir for the intestinal microbiota that exert both harmful and beneficial effects on human health; intestinal microbiota contains an extraordinarily complex variety of metabolically active bacteria and fungi which interact with the host's epithelial cells and provide constant antigenic stimulation to the mucosal immune system[1]. The intestinal epithelium presents the...
first line of defense against invading or attaching bacteria. In addition to serving as a physical barrier to microbial penetration, the intestinal mucosa is the main interface between the immune system and the luminal environment[3]. Intestinal epithelial cells (IECs) appear as an essential link in communicating with the immune cells in the underlying mucosa and the microflora in the lumen via the expression of many mediators. These mediators included antibacterial peptides such as defensins[4], mucins (MUC3), and chemokines and cytokines such as interleukin (IL)-8.

Under certain pathological circumstances, such as enteropathogens infection, the intestinal epithelium releases the chemokine IL-8 and other pro-inflammatory molecules that provoke an acute inflammatory response[5]. Therefore, a prolonged infection can result in a high level and protracted IL-8 release by IECs. The final outcome is a considerable infiltration of neutrophils that may perpetuate inflammation and eventually lead to cell damage, epithelial barrier dysfunction and pathophysiologic change of diarrhea[6].

For the protection against enteropathogen infections, the possibility of using food supplements containing probiotic bacteria has been recently considered. Probiotics are a group of live microorganisms administered in adequate amounts which confer a beneficial effect on the health of the host[7]. Most probiotics found are resident members of the intestinal flora and are of major economic importance to the food industry. Several health-related effects associated with the intake of probiotics have been reported in different animal models as well as in human studies[8]. This bacterial community plays a pivotal role in human nutrition and health by promoting the supply of nutrients, preventing pathogen colonization and shaping and maintaining normal mucosal immunity[8]. While the precise mechanistic basis of the beneficial effects of probiotics is still obscure and will most likely vary depending on the strain and species used, a number of mechanisms have been suggested[9]. Protecting the host from enteropathogen colonization (barrier effects) and immunomodulatory effects toward host immune response have been demonstrated in humans and laboratory animals[10,11].

The interaction between probiotic strains and the intestinal epithelium is a key determinant for cytokine production by enterocytes, and probably the initiating event in probiotic immunomodulatory activity, as it occurs prior to the encounter with the immune system cells. It has been reported that several strains of probiotics belonging to Bifidobacterium and Lactobacillus are highly relevant to the prevention of the invasion of tissues by enteropathogens[12]. Moreover, by inhibiting the production of IL-8 in enterocytes, these strains are also found to be effective in modulating the pro-inflammatory response in IECs challenged by enteropathogens such as Salmonella typhimurium (S. typhimurium); such induction is species and strain specific[13,14].

Since the immunomodulatory properties are strain-specific[15-17], for each probiotic strain, profiles of the cytokines secreted by lymphocytes, enterocytes and/or DCs that come into contact with the strain should be established. Strains belonging to the Bifidobacterium are the most widely used probiotic bacteria, and are included in many functional foods and dietary supplements.

We focused our study mainly on how IEC respond to widely used probiotic bacteria. The aim of this work was to study the cytokine pattern induced by the interaction of probiotics with intestinal epithelium cells. Furthermore, whether probiotic bacteria still function after inactivation was evaluated. This study may contribute to verify the pro- and anti-inflammatory properties of the strain in question and define specific clinical applications.

MATERIALS AND METHODS

Bacterial strains and related preparations
A globally consumed commercial probiotic strain Bifidobacterium lactis (B. lactis) HN019 was studied in the experiment. The B. lactis HN019 powder was a gift from Danisco. Live strain was inoculated in De Man, ROGOSA and SHARPE (MRS) broth (Difco) supplemented with 0.05% (w/v) cysteine hydrochloride at 37°C under anaerobic conditions for 24 h. The stationary-phase bacteria were harvested and Gram-stained to confirm purity. Heat-killed B. lactis HN019 were prepared by heating the bacteria at 80°C for 20 min. Effectiveness of the heat-killing method was confirmed by plating the treated bacteria on MRS agar at 37°C for 48 h. S. typhimurium ATCC 14028 was used as an enteropathogenic reference strain. S. typhimurium was cultured in Tryptone Soy broth (TSB) at 37°C with shaking overnight.

Bacteria number was estimated by measuring the absorbance at 600 nm, and correlating the absorbance value to a standard curve of colony-forming units (CFU) on MRS agar (Merek) estimated in preliminary experiments. For storage, liquid cultures of B. lactis HN019 grown for 24 h were frozen in 30% glycerol at -80°C; vacuum freeze-drying method was also applied.

Cell lines and media
INT-407 cells which derived from human intestinal epithelium, were purchased from American Type Culture Collection (ATCC strain CCL-6). Cells were grown in a humidified incubator at 37°C under 5% CO2. INT-407 cells were cultured in Dulbecco’s Modified Eagle Medium (DMEM) (GIBCO) containing 10% (v/v) heat-inactivated fetal bovine serum (Invitrogen), 50 U/mL penicillin, and 50 μg/mL streptomycin. The cells were routinely propagated in 25 cm2 tissue culture flasks until they approached 80%-90% confluences. Subsequently, the cells were subcultured and the medium was replaced every two to three days in the culturing process.

Adhesion assays
Each adhesion assay was conducted in triplicate over three to five successive passages of INT-407 cells. Briefly, INT-407 cells were seeded on sterile six-well plates and grown to 80% confluence. The monolayers of INT-407 cells were rinsed three times with modified Hank’s Balanced Salt Solution (mHBSS) without calcium and magnesium. Late exponential cultures of B. lactis HN019 or/
and *S. typhimurium* ATCC 14028 were adjusted at an optical density at 600 nm corresponding to 1 × 10^6 cells/mL. After rinsing, the bacterial cells were resuspended in DMEM and used for the adhesion assay. After incubation for 2 h and 6 h at 37°C in the atmosphere of 5% CO₂ and 95% air, unattached bacteria were removed by washing the monolayers four times with sterile PBS. After detachment of the INT-407 cells from the plastic surface by incubation with 200 μL trypsin/EDTA per well (10 min, 37°C), the INT-407 cells and the adhesive bacteria were transferred into a 1.5 mL reaction tube. The wells were rinsed with 200 μL sterile PBS which was also transferred into the 1.5 mL-reaction tube.

Bacterial adhesion to INT-407 cells was evaluated by quantification of INT-407-bound bacteria with genus-specific primers via real-time polymerase chain reaction (PCR) as reported by Candela et al. To quantify the bacterial cells by real-time PCR, the cell suspensions obtained from the adhesion assays were thawed at room temperature and, after mixing, an aliquot of 20 μL was transferred into a 0.2 mL-reaction tube and incubated for 10 min at room temperature with 3.8 μL of Trypsin inhibitor solution. Then the bacterial cells (Bifidobacterium and Salmonella) were specifically quantified by real-time PCR performed with the genus-specific primers listed in Table 1. pMD19 T-vector which carried genus-specific genes was constructed as internal standards.

Real-time PCR was performed in ABI 7500 instrument and SYBR Green I fluorophore was used to correlate the amount of PCR product with the fluorescent signal. Amplification was carried out in a 20 μL final volume containing 2 μL of cell suspension, 10 μL SYBR Premix Ex Taq (TAKARA), 0.2 μmol/L of each primer and 0.4 μL ROX Reference Dye II. The experimental protocol consisted of the following programs: starting preincubation at 95°C for 10s; amplification including 40 cycles of 95°C for 5 s, and 60°C for 34 s. Since the copy numbers of standard plasmids could be quantified, we amplified serial dilutions of the plasmids that represent bacteria number ranging from 1 × 10^2 to 1 × 10^8 CFU/μL.

The data reported represent mean values obtained in 3-5 independent experiments. Each experiment was performed in duplicate.

**Preparation of samples for electron microscopy**

INT-407 cells treated with *B. lactis* HN019 for 2 h and 6 h as previously described were washed three times with PBS buffer solution. Formaldehyde (40%) and glutaraldehyde (10%) were added for fixation. Ultrastructure of the cells was examined under transmission electron microscopy. The micrographs were produced at 5800 × and 13 500 × magnification. Cells from the control group which had not been treated with bacteria were processed in the same way. Two samples from each group were analyzed.

**INT-407 cells treatment**

Monolayer of INT-407 cells were washed in PBS and supplemented with DMEM plus 2% FBS without antibiotics overnight before infection. *B. lactis* HN019 and *S. typhimurium* ATCC 14028 was harvested in stationary-phase, centrifuged and resuspended in fresh DMEM medium. After heat-killing treatment, viable *B. lactis* HN019, *S. typhimurium* ATCC 14028 and inactivated *B. lactis* HN019 were added into six-well plates for coculture with INT-407 cells at a bacterial to epithelial cell ratio of 10:1. Untreated cells with normal medium were used as negative control. The plates were kept in humidified atmosphere containing 5% CO₂ for 2 h.

**Bacterial interference assays**

The ability of *B. lactis* to inhibit binding of *S. typhimurium* to INT-407 cells was also assessed. INT-407 cells (1 × 10^6) seeded in six-well plates in antibiotic-free medium were incubated for 24 h. After replenishing the medium, the following assays were performed. (1) Coincubation of *B. lactis* HN019 and *S. typhimurium* ATCC 14028 with INT-407 cells for 2 h; (2) INT-407 cells were pretreated with 10:1 *B. lactis* HN019 for 2 h prior to infection with 10:1 *S. typhimurium* ATCC 14028 for further 2 h; (3) INT-407 cells were pre-stimulated with 10:1 *S. typhimurium* ATCC 14028 for 2 h prior to retreatment with 10:1 *B. lactis* HN019 for further 2 h; and (4) Untreated INT-407 cells were used as baseline control.

**RNA extraction**

Following bacterial treatment, cell culture supernatants were removed and washed three times with sterile D-Hank’s. INT-407 cells collected for RNA preparation were immediately lysed in TRIZOL Reagent (Invitrogen). Total RNA was isolated from the lysed cells according to the manufacturer’s instructions. Purification of RNA was performed by RNase-free DNase and standard phenol chloroform extraction method. The quantity of RNA was evaluated by spectrophotometric analysis and the quality of RNA samples was determined based on the A260/A280 ratio. All RNA samples were further analyzed by agarose gel electrophoresis to check for the integrity of 5S, 18S and 28S rRNA.

**Real-time RT-PCR analysis**

Total RNA (2 μg) was reverse-transcribed to yield cDNA using SuperScript III First-Strand Synthesis System (Invitrogen) as the manufacturer’s protocol for the following experiments. Primers targeting four genes of interest were designed for detecting mRNA expression. Real-time RT-PCR was performed in an ABI 7500 system (Applied Biosystems) using SYBR Premix Ex Taq as mentioned.

---

**Table 1 Primer sequences of genus-specific genes used in adhesion assays**

| Primer name | Primer sequences (5’-3’) | Specificity | Ref. |
|-------------|--------------------------|-------------|------|
| BIF 164     | GGGTGGAATGCGGATG         | Bifidobacterium | [21] |
| BIF 662     | CCGCGGTTACACCGGAAG       |              |      |
| MNf         | ACGGTAAACGGAAGCAG        | Salmonella    | [24] |
| MNr         | TATTAACCACAAACCT         |              |      |

---
above. Calculations were performed using β-actin as an internal standard. Primer sequences are shown in Table 2. All reactions were performed in triplicate. Relative gene expression data was determined by the \(2^{-\Delta\Delta CT}\) method as previously described\[19\]. Fold changes > 2 or < -0.5 was defined as significantly changed between treated and untreated cells.

**IL-8 ELISA**

Subconfluent or confluent INT-407 cells were incubated with varying groups of bacteria: (1) Cells were incubated with *B. lactis* HN019 or heat-killed *S. typhimurium* ATCC 14028 at a bacterial to epithelial cell ratio of 10:1 for 12 h; (2) Confluent monolayers of INT-407 cells were stimulated with 10 ng/mL LPS (derived from *S. typhimurium*, Sigma) for 12 h; (3) INT-407 cells were co-incubated with *B. lactis* HN019 (multiplicity of infection = 10) and LPS (10 ng/mL) simultaneously for 12 h; (4) Pretreated with 10:1 *B. lactis* HN019 for 2 h prior to stimulation with 10 ng/mL LPS for further 12 h; (5) Pre-stimulated with 10 ng/mL LPS for 2 h, and then treated with 10:1 *B. lactis* HN019 for further 12 h; and (6) Untreated cells were used as negative control. Cells from all treatments were washed three times with PBS. Immunoreactive IL-8 protein levels in cell-culture supernatants were quantified using an ELISA DuoSet kit (R & D Systems) according to the manufacturer’s protocol.

**Statistical analysis**

Values were given as mean ± SD of triplicate measurements. Statistical analyses were performed using unpaired two-tailed Student’s *t* test. *P* value < 0.05 was considered to be statistically significant.

**RESULTS**

**Inhibitory effects of *B. lactis* HN019 on *S. typhimurium* ATCC 14028 attachment**

The *B. lactis* HN019 strains in this study were evaluated with regard to their ability to inhibit the attachment of pathogenic *S. typhimurium* ATCC 14028 to INT-407 cells. Adherence activity of *B. lactis* HN019 and/or *S. typhimurium* ATCC 14028 was evaluated by a real-time PCR as shown in Figure 1.

**Table 2** Primer sequences used for quantitative real-time PCR analysis

| Gene   | Primer sequences (5’-3’) | Product size (bp) |
|--------|--------------------------|-------------------|
| IL-1β  | ACTCAGTTAAGGCGCCCTG      | 80                |
|        | TCGAGAATGCGGAGCAATG      |                   |
| IL-8   | CAAGAGCCAGGAAGAAACCAC    | 101               |
|        | TGGAGAAATCCGAAAGGCCTG    |                   |
| TNF-α  | TCTTCTGCAAAGGCCAGTG      | 150               |
|        | CTTCTGATGCCACCAACAG      |                   |
| β-actin| TGGATTACAGGAAGTCCTTCGCC  | 101               |
|        | AATCTATACACCTCCCTGTG     |                   |

PCR: Polymerase chain reaction; IL: Interleukin; TNF: Tumor necrosis factor.

Candela et al[18] defined bacterial strains as non-adhesive with less than 5 bacterial cells adhered to one cell. Following this adhesion score, both *B. lactis* HN019 and *S. typhimurium* ATCC 14028 could effectively adhere to INT-407 cells. Moreover, the adhesive capacity of *B. lactis* HN019 was not higher than *S. typhimurium* ATCC 14028 when treated with either strain alone, showing the adherence values of 5.29 × 10² and 6.99 × 10² bacterial cells/100 INT-407 cells after 2 h while 1.53 × 10³ and 2.08 × 10³ bacterial cells/100 INT-407 cells after 6 h. Nevertheless, the adhesion values obtained in co-treated assays showed that the *B. lactis* HN019 could significantly decrease the attached number of *S. typhimurium* ATCC 14028 from 2.08 × 10³ to 5.85 × 10² bacterial cells/100 INT-407 cells after 6 h treatment, and the number of attached *B. lactis* HN019 was not affected by the existence of *S. typhimurium* ATCC 14028.

**Transmission electron microscopy studies**

In these studies we observed that *B. lactis* HN019 was able to interact with the epithelial cells of small intestine (Figure 2), and it was interesting that the *B. lactis* HN019...
could be internalized into the INT-407 cells after 6 h treatment.

**Inflammatory gene expression following bacteria incubation**

Inflammatory gene expression in bacteria-treated INT-407 cells was analyzed with real-time PCR. The results showed that live *B. lactis* HN019 had no effect on gene expression of IL-1β, but could up-regulate TNF-α expression and down-regulate IL-8 expression. Heat-killed *B. lactis* HN019 had no effect on gene expression of IL-1β, IL-8 and TNF-α. Pathogenic *S. typhimurium* ATCC 14028 could significantly up-regulate the mRNA level of pro-inflammatory cytokines. Although co-incubation with *B. lactis* HN019 and *S. typhimurium* ATCC 14028 could induce the gene expression of TNF-α and IL-1β, the extent is significantly lower than in those stimulated with *S. typhimurium* ATCC 14028 alone (Figure 3).

In bacterial interference assays, IL-1β, IL-8 and TNF-α mRNA expression was not changed at baseline after pre-treated with *B. lactis* HN019, and addition with *S. typhimurium* ATCC 14028 also did not activate these pro-inflammatory cytokines expression. For groups pre-stimulated with *S. typhimurium* ATCC 14028, *B. lactis* HN019 lowered the *S. typhimurium* ATCC 14028 induced IL-1β, IL-8 and TNF-α levels from 8.73, 47.97 and 9.3 folds to 2.6, 0.89 and 0.37 folds as compared with the untreated group. The results are summarized in Figure 3.

Through either incubating the INT-407 cells with *B. lactis* HN019 and *S. typhimurium* ATCC 14028 simultaneously or pre-treating with each strain respectively, the pro-inflammatory cytokines induced by *S. typhimurium* ATCC 14028 could be suppressed by *B. lactis* HN019. We therefore compared the inhibitory effects of these three groups and found that for IL-1β, the inhibition rate of *B. lactis* HN019 pretreated group was much lower than the other two groups. For IL-8, there was no significant difference among the three groups. For TNF-α, the inhibition rate of co-treated group was much lower than the other two groups (Figure 4).

**IL-8 secretion by INT-407 cells following bacteria incubation**

To assess the effects of probiotic strain on IL-8 secretion, INT-407 cells were incubated with live or heat-killed *B. lactis* and *S. typhimurium* and/or lipopolysaccharide. The experiments were performed 2-5 times in replicate; the results are demonstrated in Figure 5.

Firstly, we tested the effects of live *B. lactis* HN019, heat-killed *B. lactis* HN019 and *S. typhimurium* ATCC 14028, LPS derived from *S. typhimurium* on IL-8 secretion. The results showed that both live and dead *B. lactis* HN019 decreased IL-8 levels (844 ± 64 pg/mL and 897 ± 80 pg/mL) compared with the untreated group (1963 ± 77 pg/mL). Co-culturing with heat-killed *S. typhimurium* ATCC 14028 induced no change in IL-8 concentration. However, stimulation of INT-407 cells with LPS resulted in a significant increase of IL-8 production (3104 ± 80 pg/mL).

Secondly, in order to assess the anti-inflammatory
properties of the probiotic strain, the IL-8 production was evaluated by incubating INT-407 cell monolayers with *B. lactis* HN019 in the presence of LPS. As presented in Figure 5, IL-8 protein level secreted by the cells noticeably increased after co-incubated with LPS and probiotic strain compared with untreated group. However, the probiotic strain could decrease the LPS-induced IL-8 expression, and the cells pretreated with probiotic strain could also remain at a low level IL-8 secretion even after re-stimulated with LPS as compared with untreated group. This suggests that this probiotic strain *B. lactis* HN019 exerted anti-inflammatory effects on the epithelium by down-regulating the secretion of IL-8.

**DISCUSSION**

The role of probiotic bacteria derived from normal intestinal microbiota in the physiology of the gastrointestinal tract is not completely understood. In particular, the mechanisms underlying the benefits from biotherapy with probiotics have not been sufficiently elucidated. *B. lactis* HN019 is a world-wide consumed probiotic strain which is associated with several health-related immunomodulatory effects: such as reducing the severity of pathogen infection and enhancing immunity in the elderly. Nevertheless, the mechanism is yet to be known. This is the first study on the differential pro-inflammatory cytokine responses of intestinal epithelium under conditions employing live and heat-killed *B. lactis* HN019. Furthermore, the enteropathogen exclusion effect of *B. lactis* HN019 was not evaluated.

In the present study, we used a rapid, accurate and sensitive method for studying bacteria adhesion. Provided specific primers for bifidobacteria are known, our method allows the quantification of this organism’s cell number adhering to INT-407 cells which is used as a model in our investigation. A further important advantage of the real-time PCR based method is its efficacy in detecting and quantifying different bacterial genera and species simultaneously adhering to an epithelial cell monolayer. This method can be useful for probiotic strain selection. By this method, we found that *B. lactis* HN019 exerted a strong adhesive activity to human intestinal epithelial cells INT-407. The ability to adhere to the intestinal epithelium represents a significant prerequisite for the transient intestinal colonization of probiotic bacteria.

Bifidobacteria are normal gastrointestinal flora of many animals and have been shown to be adherent to a variety of epithelial cells *in vitro*. However, adherence to INT-407 cells is seldom reported. This adherence to INT-407 cells may be mediated via fibronectin binding. It is known that probiotic strains have the ability to counteract the pathogenic bacteria invasion. In particular, the bifidobacteria strain tested is effective in inhibiting the adhesion of pathogenic *S. typhimurium* ATCC 14028 to INT-407 cells. This behavior is a fundamental prerequisite for probiotic bacteria to exert antagonistic activities against enteropathogens. Such inhibitory effects of bifidobacteria can be explained by the mechanisms of competition for common adhesive sites or producing antibacterial lipophilic factor(s). In addition, it is reported that bifidobacteria could produce a proteinaceous factor that inhibits *in vitro* adherence of an enterotoxigenic *E. coli* strain to gangliotetraosylceramide molecules, which are physiological constituents of the mammalian intestinal epithelial surface.

Interactions of *B. lactis* HN019 and INT-407 cells observed under transmission electron microscope (TEM) indicated that the bacteria are able to contact with the epithelial cells of the small intestine. Moreover, the *B. lactis* HN019 could be internalized into INT-407 cells. It has been described that pathogens (bacteria, virus and parasites) can cross the mucosal barrier through different routes: transcellular route, paracellular route across cells for the tight junctions and via M cells. The *B. lactis* used in this study was originally isolated from a human host. Therefore, it may be that this strain can internalize into epithelial cells because of its host specificity. We considered that such internalization may be of potential risks if the safety status of the internalized bacteria were not carefully assessed, especially the translocation capacity which correlate with its ability to induce infections.
The colonization of the intestinal tract by enteropathogenic bacteria induces the activation of the inflammatory cascade, resulting in the epithelial cell secretion of IL-8 and other pro-inflammatory molecules and in the consequent recruitment of neutrophils and other inflammatory cells. IL-8 amplifies an ongoing acute immune response and provides a set of signals for the activation of mucosal inflammatory responses in the earliest phases of microbial invasion. In some cases, a massive and prolonged infiltration of neutrophils may perpetuate inflammation and ultimately lead to cell damage, epithelial barrier dysfunction and pathophysiologic change of diarrhea. In the present study, INT-407 cells behaved like human enterocytes and could secrete IL-8 either constitutively or after stimulation with physiological agonists. Probiotic strains presented differences in their capacity to augment IL-8 expression, however, some strains seemed to rather decrease epithelial-cell production of IL-8[15-17,34-36]. Our results showed a robust IL-8 expression of INT-407 cells induced when exposed to S. typhimurium. However, live and heat-killed B. lactis HN019 not only functionally modulate the epithelium by inhibiting the constitutive mRNA level of IL-8 and attenuating S. typhimurium-induced IL-8 gene expression, but also protect the INT-407 cells from IL-8 protein production activated by LPS. The same results were discovered on TNF-α and IL-1β gene expression except for up-regulation of TNF-α expression by live B. lactis HN019, but the S. typhimurium could induce much higher TNF-α expression than live B. lactis HN019. High concentrations of IL-1β and TNF-α cause cachexia, tissue injury, disseminated intravascular coagulation and shock. Therefore, the control of secretion of these pro-inflammatory cytokines in vivo is very important. B. lactis HN019 has a beneficial effect in converting the infection-induced excessive cytokine expression and helping maintain an immunological balance. These data indicated that INT-407 displayed immunological quiescence when exposed to both live and dead B. lactis HN019. B. lactis HN019 can modulate epithelial responses to limit inflammatory signals and markedly inhibit the inflammatory response induced by pathogen.

We used three approaches to detect the influence of probiotic strain on the pathogenic strain, and found that although the B. lactis HN019 could reduce the expression of pro-inflammatory cytokines, the inhibitory effect was different depending on the treatment methods. Pre-stimulated INT-407 cells with S. typhimurium ATCC 14028 could strongly induce a high-level of pro-inflammatory cytokine expression and such up-regulation could be reversed to a normal level after re-treatment with probiotic B. lactis HN019. This treatment achieved the maximum inhibitory rate. These results indicated that B. lactis HN019 may be more effective as adjunctive therapeutic agent than as preventive agent in inflammatory diseases.

In conclusion, our studies revealed that as a probiotic strain, B. lactis HN019 could modulate immune system towards anti-inflammatory action and exclude enteropathogenic adhesion. These findings may help with better applications of the B. lactis HN019 and will contribute to offering new therapeutic means to counteract the inflammatory disorders observed in human inflammatory bowel disease.

ACKNOWLEDGMENTS

The authors thank Dr. Susan Jin from Danisco Shanghai Center for kindly providing us with probiotic products.

REFERENCES

1. Tiškalová-Hogenová H, Štepánková R, Hudovic T, Tucková L, Cukrowska B, Lodinová-Zádníková R, Kozákůvá H, Rossmann P, Bártová J, Sokol D, Funda DP, Borovská D, Reháková Z, Sinkovna J, Hofman J, Drastich P, Kokesová A. Commensal bacteria (normal microflora), mucosal immunity and chronic inflammatory and autoimmune diseases. Immunol Lett 2004; 93: 97-108
2. Wershil BK, Furuta GT. 4. Gastrointestinal mucosal immunity. J Allergy Clin Immunol 2008; 121: S280-S283; quiz 5415
3. Takahashi A, Wada A, Ogushi K, Maeda K, Kawahara T, Mawatari K, Kurazono H, Moss J, Hirayama T, Nakaya Y. Production of beta-defensin-2 by human colonic epithelial cells induced by Salmonella enteritidis flagella filament structural protein. FEBS Lett 2001; 508: 484-488
4. MacDonald TT, Monteleone G. Immunity, inflammation, and allergy in the gut. Science 2005; 307: 1920-1925
5. Roselli M, Finamore A, Britti MS, Mengheri E. Probiotic bacteria Bifidobacterium animalis MB5 and Lactobacillus rhamnosus GG protect intestinal Caco-2 cells from the inflammation-associated response induced by enterotoxigenic B. lactis HN019. This finding will offer, in the near future, new therapeutic means to counteract the inflammatory disorders observed in human inflammatory bowel disease.

ACKNOWLEDGMENTS

The authors thank Dr. Susan Jin from Danisco Shanghai Center for kindly providing us with probiotic products.

REFERENCES

1. Tiškalová-Hogenová H, Štepánková R, Hudovic T, Tucková L, Cukrowska B, Lodinová-Zádníková R, Kozákůvá H, Rossmann P, Bártová J, Sokol D, Funda DP, Borovská D, Reháková Z, Sinkovna J, Hofman J, Drastich P, Kokesová A. Commensal bacteria (normal microflora), mucosal immunity and chronic inflammatory and autoimmune diseases. Immunol Lett 2004; 93: 97-108
2. Wershil BK, Furuta GT. 4. Gastrointestinal mucosal immunity. J Allergy Clin Immunol 2008; 121: S280-S283; quiz 5415
3. Takahashi A, Wada A, Ogushi K, Maeda K, Kawahara T, Mawatari K, Kurazono H, Moss J, Hirayama T, Nakaya Y. Production of beta-defensin-2 by human colonic epithelial cells induced by Salmonella enteritidis flagella filament structural protein. FEBS Lett 2001; 508: 484-488
4. MacDonald TT, Monteleone G. Immunity, inflammation, and allergy in the gut. Science 2005; 307: 1920-1925
5. Roselli M, Finamore A, Britti MS, Mengheri E. Probiotic bacteria Bifidobacterium animalis MB5 and Lactobacillus rhamnosus GG protect intestinal Caco-2 cells from the inflammation-associated response induced by enterotoxigenic
Liu C et al. Adhesion and immunomodulatory effects of B. lactis HN019

Escherichia coli K88. Br J Nutr 2006; 95: 1177-1184

6 Hezcko PB, Strus M, Kochan P. Critical evaluation of probiotic activity of lactic acid bacteria and their effects. J Physiol Pharmacol 2006; 57 Suppl 9: 5-12

7 Roberfroid MB. Probiotics and probiotics: are they functional foods? Am J Clin Nutr 2001; 71: 1682S-1687S; discussion 1688S-1690S

8 Parvez S, Malik KA, Ah Kang S, Kim HY. Probiotics and their fermented food products are beneficial for health. J Appl Microbiol 2006; 100: 1171-1185

9 Boirivant M, Strober W. The mechanism of action of probiotics. Curr Opin Gastroenterol 2007; 23: 679-692

10 Nova E, Wärnberg J, Gómez-Martínez S, Díaz LE, Romeo J, Marcos A. Immunomodulatory effects of probiotics in different stages of life. Br J Nutr 2007; 98 Suppl 1: S90-S95

11 Resta-Lenert S, Barrett KE. Live probiotics protect intestinal epithelial cells from the effects of infection with enteroinvasive Escherichia coli (EIEC). Gut 2003; 52: 988-997

12 Fooks LJ, Gibson GR. Probiotics as modulators of the gut flora. Br J Nutr 2002; 88 Suppl 1: S39-S49

13 Ruiz PA, Hoffman M, Sacesny S, Blaut M, Haller D. Innate mechanisms for Bifidobacterium lactis to activate transient pro-inflammatory host responses in intestinal epithelial cells after the colonization of germ-free rats. Immunology 2005; 115: 441-450

14 Vinderola G, Matar C, Perdigon G. Role of intestinal epithelial cells in immune effects mediated by gram-positive probiotic bacteria: involvement of toll-like receptors. Clin Diagn Lab Immunol 2005; 12: 1079-1084

15 Lammers KM, Helwig U, Swennen E, Rizzello F, Venturi A, Caramelli E, Kamm MA, Brigidi P, Gionchetti P, Campieri M. Effect of probiotic strains on interleukin 8 production by HT29/19A cells. Am J Gastroenterol 2002; 97: 1182S-1186S

16 Otte JM, Podolesky DK. Functional modulation of enterocytes by gram-positive and gram-negative microorganisms. Am J Physiol Gastrointest Liver Physiol 2004; 286: G613-G626

17 McCracken VJ, Chan T, Baldeón ME, Ahnê S, Molin G, Mackie RI, Gaskins HR. TNF-alpha sensitizes HT-29 colonic epithelial cells to intestinal lactobacilli. Exp Biol Med (Maywood) 2002; 227: 665-670

18 Candela M, Seibold G, Vitali B, Lachenmaier S, Eikmanns B, Yamazaki S. Probiotics and safety. Br J Nutr 2000; 84: 402-408

19 Gill HS, Rutherford KJ, Cross ML, Gopal PK. Enhancement of immunity in the elderly by dietary supplementation with the probiotic Bifidobacterium lactis HN019. Am J Clin Nutr 2001; 74: 833-839

20 Shu Q, Lin H, Rutherford KJ, Fenwick SG, Prasad J, Gopal PK, Gill HS. Dietary Bifidobacterium lactis (HN019) enhances resistance to oral Salmonella typhimurium infection in mice. Microbiol Immunol 2000; 44: 213-222

21 Shu Q, Gill HS. A dietary probiotic (Bifidobacterium lactis HN019) reduces the severity of Escherichia coli O157:H7 infection in mice. Med Microbiol Immunol 2001; 189: 147-152

22 Tuomola E, Crittenden R, Playne M, Isolauri E, Salminen S. Quality assurance criteria for probiotic bacteria. Am J Clin Nutr 2001; 73: 3938-3985

23 Collado MC, Gueimonde M, Hernández M, Sanz Y, Salminen S. Adhesion of selected Bifidobacterium strains to human intestinal mucus and the role of adhesion in enteropathogen exclusion. J Food Prot 2005; 68: 2672-2678

24 Karppanen DR, Meinersmann RJ, Lee MD. Adherence of Lactobacillus to intestinal 407 cells in culture correlates with fibronectin binding. Curr Microbiol 2000; 41: 136-141

25 Candela M, Perna F, Carnevali P, Vitali B, Ciati R, Gionchetti P, Rizzello F, Campieri M, Brigidi P. Interaction of probiotic Lactobacillus and Bifidobacterium strains with human intestinal epithelial cells: adhesion properties, competition against enteropathogens and modulation of IL-8 production. Int J Food Microbiol 2008; 125: 286-292

26 Gopal PK, Prasad J, Smart J, Gill HS. In vitro adhesion properties of Lactobacillus rhamnosus DR20 and Bifidobacterium lactis DR10 strains and their antagonistic activity against an enterotoxogenic Escherichia coli. J Int Food Microbiol 2001; 67: 207-216

27 Bernet MF, Brascott D, Neesser JR, Servin AL. Lactobacillus acidophilus LA 1 binds to cultured human intestinal cell lines and inhibits cell attachment and cell invasion by enterovirulent bacteria. Gut 1994; 35: 483-489

28 Liévin V, Peiffer J, Hudault S, Rochat F, Brascott D, Neesser JR, Servin AL. Bifidobacteria strains from resident infant human gastrointestinal microflora exert antimicrobial activity. Gut 2000; 47: 646-652

29 Fujiwara S, Hashiba H, Hirota T, Forster NJ. Purification and characterization of a novel protein produced by Bifidobacterium longum SBT2928 that inhibits the binding of enterotoxogenic Escherichia coli Ph176 (CFA/I) to gangliotetraosylceramide. J Appl Microbiol 1999; 86: 615-621

30 Hershberg RM, Mayer LF. Antigen processing and presentation by intestinal epithelial cells-polarity and complexity. Immunol Today 2000; 21: 123-128

31 Ishibashi N, Yamazaki S. Probiotics and safety. Am J Clin Nutr 2001; 73: 4655-4705

32 Ma JY, Tytgat GJN. Probiotics: the current status and the future. J Gastroenterol Hepatol 2002; 17 Suppl 4: 1-2

33 Ma WH, You Z. The role of probiotics in human gastrointestinal diseases. World J Gastroenterol 2003; 9: 2476-2480

34 Ma D, Forsythe P, Bienenstock J. Live Lactobacillus reuteri is essential for the inhibitory effect on tumor necrosis factor alpha-induced interleukin-8 expression. Infect Immun 2004; 72: 5308-5314

35 Bai AP, Ouyang Q, Zhang W, Wang CH, Li SF. Probiotics inhibit TNF-alpha-induced interleukin-8 secretion of HT29 cells. World J Gastroenterol 2004; 10: 455-457

36 Wang S, Ng LH, Chow WL, Lee YK. Infant intestinal Enterococcus faecalis down-regulates inflammatory responses in human intestinal cell lines. World J Gastroenterol 2008; 14: 1067-1076

37 Kok RG, de Waal A, Schut F, Welling GW, Weenk G, Hellings GW. Specific detection and analysis of a probiotic Bifidobacterium strain in infant feces. Appl Environ Microbiol 1996; 62: 3668-3672

38 Trkov M, Avgustin G. An improved 16S rRNA based PCR method for the specific detection of Salmonella enterica. Int J Food Microbiol 2003; 80: 67-75

S-Editor Wang YR L-Editor Ma JY E-Editor Ma WH